Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

2297 - Phase II study to evaluate the peripheral blood mononuclear cell biomarker for nivolumab efficacy on previously treated non-small cell lung cancer subjects (NEJ029B: IMMUNITY-ONE)


28 Sep 2019


Poster Display session 1


Tumour Site

Non-Small Cell Lung Cancer


Yosuke Kawashima


Annals of Oncology (2019) 30 (suppl_5): v602-v660. 10.1093/annonc/mdz260


Y. Kawashima1, O. Yamaguchi2, T. Kozuki3, N. Furuya4, F. Kurimoto5, T. Okuno6, T. Yamada7, K. Komiyama8, R. Ko9, Y. Nagai10, N. Ishikawa11, T. Harada12, K. Watanabe13, M. Seike14, K. Yoshimura15, K. Kobayashi16, H. Kagamu2

Author affiliations

  • 1 Department Of Pulmonary Medicine, Sendai Kousei Hospital, 980-0873 - Sendai/JP
  • 2 Department Of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama/JP
  • 3 Department Of Thoracic Oncology And Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama/JP
  • 4 Division Of Respiratory Medicine, Department Of Internal Medicine, St. Marianna University School of Medicine, 216-8511 - Kawasaki/JP
  • 5 Thoracic Oncology, Saitama Cancer Center, Saitama/JP
  • 6 Department Of Internal Medicine, Shimane University Faculty of Medicine, Izumo/JP
  • 7 Department Of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto/JP
  • 8 Department Of Respiratory Medicine, Saitama Medical University Hospital, Saitama/JP
  • 9 Department Of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo/JP
  • 10 Department Of Pulmonary Medicine, Jichi Medical University, Tochigi/JP
  • 11 Department Of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima/JP
  • 12 Center For Respiratory Diseases, JCHO Hokkaido Hospital, 062-8618 - Sapporo/JP
  • 13 Department Of Respiratory Medicine, Miyagi Cancer Center, Natori/JP
  • 14 Division Of Pulmonary Medicine And Oncology, Graduate School of Medicine, Nippon Medical School, 1138603 - Tokyo/JP
  • 15 Department Of Biostatistics, Innovative Clinical Research Center, Kanazawa University Hospital, 920-8641 - Kanazawa/JP
  • 16 Department Of Respiratory Medicine, Saitama Medical University International Medical Center, 350-1298 - Saitama/JP


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 2297


Although anti-PD-1 antibodies are the most promising agents in advanced non-small cell lung cancer (NSCLC), no definitive biomarkers of efficacy exist. We developed a novel assay for peripheral blood mononuclear cell (PBMC) biomarker using the prediction formula consisting of CD62L-downregulated (CD62Llow) CD4+T cells and CD25+Foxp3+CD4+T cells. This study aimed to validate it.


This prospective multicenter phase II study included patients with treated advanced or metastatic NSCLC. After registration and PBMC biomarker analysis, they were classified into responder (RT) or non-responder (NRT) type. Nivolumab was administered every two weeks. The primary endpoint was disease control rate (DCR) at nine weeks after nivolumab treatment in RT patients. Desired and threshold DCR were set at 80% and 60%, respectively. Secondary endpoints were objective response rate (ORR), time to treatment failure, progression-free survival (PFS), overall survival, safety and tolerability, comparison with NRT patients, and PBMC biomarker quality improvement.


Of the 96 enrolled patients, 95 were eligible for PBMC analysis: 3 were unanalyzable, and 92 were analyzed; however, 40 had a minimal number of live cells. We excluded 19 patients who did not receive nivolumab in NRT and 1 with indeterminable treatment effect at nine weeks, and 72 patients comprised the per protocol set (PPS), of which 43 were RT and 29 NRT. The DCR and ORR in RT patients were 65.1% (95% confidence interval [CI], 50.9-79.4%) and 14.0% (95% CI, 3.6-24.3%), respectively. The PFS in RT patients was 113 days (95% CI, 65-158). As a subset analysis, we examined 45 patients (25 RT and 20 NRT) excluding those with ≥50% dead cell ratio in lymphocyte culture. The DCR was 80.0% (95%CI, 64.3-95.7) in RT and 50.0% (95% CI, 28.1-71.9) in NRT (chi-square test, p = 0.034).


In alive PBMC analysis, DCR was better in the RT than in the NRT patients. This PBMC biomarker using the ratio of CD62LlowCD4+T cells to CD25+Foxp3+CD4+T cells might be promising for predicting nivolumab efficacy.

Clinical trial identification

UMIN ID: UMIN000028468.

Editorial acknowledgement

Legal entity responsible for the study

North East Japan Study Group (NEJSG).


Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K.


O. Yamaguchi: Research grant / Funding (institution): Nihon Medi-Physics Co., Ltd.; Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Ono Pharmaceutical; Speaker Bureau / Expert testimony: Bristol-Myers Squibb. T. Kozuki: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Nippon Beohringer Ingelheim Co.; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical Co.; Honoraria (self): Kyowa-Hakko Kirin; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan; Research grant / Funding (institution): Merck Biopharm; Honoraria (self): MSD; Honoraria (self): Ono Pharmaceutical Co.; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical Co. N. Furuya: Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Lilly; Honoraria (self): Chugai Pharma ; Honoraria (self): AstraZeneca; Honoraria (self): Pfizer; Honoraria (self): Taiho Pharmaceutical; Honoraria (self): Ono Pharmaceutical. T. Yamada: Research grant / Funding (self): Ono Pharmaceutical Co., Ltd.; Research grant / Funding (self): Boehringer Ingelheim Japan Inc.; Research grant / Funding (self): Takeda Pharmaceutical Co. Ltd.; Research grant / Funding (self): Chugai Pharmaceutical Co., Ltd. R. Ko: Honoraria (self): Ono Pharmaceutical Co., Ltd. T. Harada: Honoraria (institution): Boehringer Ingelheim; Honoraria (institution): Hisamitsu Pharmaceutical Co., Inc; Honoraria (institution): GlaxoSmithKleine K.K. M. Seike: Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb. K. Yoshimura: Honoraria (self): Chugai Pharma. K. Kobayashi: Speaker Bureau / Expert testimony: AstraZeneca; Speaker Bureau / Expert testimony: Boehringer Ingelheim; Speaker Bureau / Expert testimony: Taiho Pharmaceutical Company; Speaker Bureau / Expert testimony: Ono Pharmaceutical Company. H. Kagamu: Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Chugai Pharmaceutical; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Eli Lilly Japan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.